|
gptkbp:instanceOf
|
antiviral drug
protease inhibitor
|
|
gptkbp:approvalYear
|
1997
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AE04
|
|
gptkbp:brand
|
gptkb:Viracept
|
|
gptkbp:CASNumber
|
159989-64-7
|
|
gptkbp:chemicalFormula
|
contains sulfonamide group
|
|
gptkbp:contraindication
|
hypersensitivity to nelfinavir
|
|
gptkbp:developedBy
|
antiretroviral therapy
|
|
gptkbp:discoveredBy
|
gptkb:Agouron_Pharmaceuticals
|
|
gptkbp:drugClass
|
protease inhibitor
|
|
gptkbp:eliminationHalfLife
|
3.5-5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstSynthesized
|
1995
|
|
gptkbp:hasMolecularFormula
|
C32H45N3O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nelfinavir
|
|
gptkbp:interactsWith
|
gptkb:CYP2C19
gptkb:CYP3A4
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
inhibits HIV-1 protease
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
rash
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:J05AE
|
|
gptkbp:bfsLayer
|
6
|